SWOG clinical trial number
CTSU/ARST1321
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Closed
Phase
Abbreviated Title
Pazopanib Neoadjuvant Non-Rhabdomyosarcoma Soft Tissue Sarcomas in preop chemoradiation or preop radiation +/- pazopanib
Status Notes
ARST1321 was permanently closed to accrual on 1/22/19.
Available AYA Training:
How to Enroll onto AYA Studies slideset is accessible from:
https://www.ctsu.org/readfile.aspx?sectionid=166924 and the corresponding audio
recording is accessible from: https://www.ctsu.org/readfile.aspx?sectionid=166925.
Access to NCTN AYA Trials Webinar slideset is accessible from:
https://www.ctsu.org/readfile.aspx?sectionid=156366 and the corresponding audio
recording is accessible from:
https://ctwestat.webex.com/ctwestat/lsr.php?RCID=23cf391fc69844928d537d8ec80167b5.
Activated by COG/NRG: 7/7/2014
Activated by SWOG: 3/15/2016
Available AYA Training:
How to Enroll onto AYA Studies slideset is accessible from:
https://www.ctsu.org/readfile.aspx?sectionid=166924 and the corresponding audio
recording is accessible from: https://www.ctsu.org/readfile.aspx?sectionid=166925.
Access to NCTN AYA Trials Webinar slideset is accessible from:
https://www.ctsu.org/readfile.aspx?sectionid=156366 and the corresponding audio
recording is accessible from:
https://ctwestat.webex.com/ctwestat/lsr.php?RCID=23cf391fc69844928d537d8ec80167b5.
Activated by COG/NRG: 7/7/2014
Activated by SWOG: 3/15/2016
Activated
03/15/2016
Closed
01/22/2019
Participants
NCIC-CTG, COG, ALLIANCE, ECOG-ACRIN, NRG
Research committees
Early Therapeutics & Rare Cancers
Treatment
Pazopanib
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open
SWOG Clinical Trial Number
S2012
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12/02/2021
Accrual
26%
Open
Phase